{"id":246661,"date":"2010-01-29T12:33:59","date_gmt":"2010-01-29T17:33:59","guid":{"rendered":"http:\/\/www.aboutlawsuits.com\/?p=7908"},"modified":"2010-01-29T12:33:59","modified_gmt":"2010-01-29T17:33:59","slug":"european-union-calls-for-meridia-recall-and-ban","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/246661","title":{"rendered":"European Union Calls for Meridia Recall and Ban"},"content":{"rendered":"<p>European Union (EU) medical experts have called for a recall of Meridia, saying that the weight-loss drug&#8217;s safety risks outweigh its benefits and that it is too dangerous for public use.  <span id=\"more-7908\"><\/span><\/p>\n<p>The recommendations by the European Medical Agency&#8217;s Committee for Medicinal Products for Human Use came as the <a href=\"http:\/\/www.aboutlawsuits.com\/meridia-heart-attack-and-stroke-risk-warnings-7776\/\">FDA warned against use of the drug among patients with heart problems<\/a>. Marketed as Meridia in the U.S., the sibutramine-based drug is sold in Europe as Reductil, Reduxade, and Zelium. The committee&#8217;s recommendations must be approved by the European Commission.<\/p>\n<p>On January 21, the FDA said the drug&#8217;s heart risks require that it not be used in patients with a history of cardiovascular disease, such as congestive heart failure, stroke, and hypertension.  However, the agency has thus far not indicated whether a <a href=\"http:\/\/www.aboutlawsuits.com\/meridia-recall-urged-by-public-citizen-7204\/\">Meridia recall<\/a> will be issued.  The consumer group Public Citizen filed a petition with the FDA late last year calling for a Meridia ban, citing additional information from a recent study that found the weight-loss drug may increase the risk of heart attacks, strokes and other cardiovascular problems<\/p>\n<p><a href=\"http:\/\/www.aboutlawsuits.com\/meridia-7200\/\">Meridia<\/a> (sibutramine) was approved by the FDA in 1997 as a prescription-only weight loss supplement for obese patients with other risk factors such as diabetes, high cholesterol and controlled blood pressure.<\/p>\n<p>In November 2009, the FDA announced that they were reviewing potential <a href=\"http:\/\/www.aboutlawsuits.com\/meridia-side-effects-being-reviewed-by-fda-7055\/\">heart problems from Meridia<\/a> after data suggested that side effects of the drug may cause users to suffer a higher number of cardiovascular events, such as heart attacks, strokes, resuscitated cardiac arrest or death.<\/p>\n<p>The review was announced after FDA began examining data from a 10,000-patient study conducted in Europe known as the Sibutramine Cardiovascular Morbidity\/Mortality Outcomes in Overweight or Obese Subjects at Risk of Cardiovascular Event (SCOUT). The latest recommendations came after further review of that data.<\/p>\n<p>European medical experts were also consulting the SCOUT data when they came to the conclusion that the drug should be banned.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>European Union (EU) medical experts have called for a recall of Meridia, saying that the weight-loss drug&#8217;s safety risks outweigh its benefits and that it is too dangerous for public use. The recommendations by the European Medical Agency&#8217;s Committee for Medicinal Products for Human Use came as the FDA warned against use of the drug [&hellip;]<\/p>\n","protected":false},"author":3957,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-246661","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/246661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/3957"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=246661"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/246661\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=246661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=246661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=246661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}